ETIOPATOGENIA EXISTE BASE GENETICA? PORQUE RESPONDE AL OH? QUE ESTRUCTURAS CAUSAN EL TEMBLOR? CUAL ES EL NT MAS IMPORTANTE? EXISTE DETERIORO COGNITIVO?

Slides:



Advertisements
Similar presentations
Christine Baldwin Department of Medicine & Therapeutics
Advertisements

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study Garcia-Manero G et al. Proc ASH 2010;Abstract 603.
Defining suboptimal response to MS treatment: MRI outcome
Balance Control Improves Following Replacement of Paroxetine with Venlafaxine and Levodopa in a Case of Microvascular Dementia The American Journal of.
Dr Tom Gilhooly. MS Prevalence Scotland – highest rate in the world UK ~ 85,000 sufferers Rate of per 100,000 population Northern Europe.
Module II The Basics of the Brain, the Body and Drug Actions
Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which? Lockhart BP, Lestage PJ. January 2003.
Design of Dose Response Clinical Trials
NTDB ® Annual Report 2010 © American College of Surgeons All Rights Reserved Worldwide National Trauma Data Bank 2010 Annual Report.
Behavioral Health Forum: Integrating the Science and the Practice for the Future University of Texas MD Anderson Cancer Center Houston, Texas – June 8,
1 1  1 =.
The Use of Vitamin D in Clinical Practice
Arianna Ahiagbe ‘12 Human Biology, Sc.B. Thesis Adviser: Bruce Becker, MD, MPH Second Reader: John Marshall, Ph.D. ADHD, INJURY, AND MEDICATION ADHERENCE.
This slide set is designed for educational presentations about TheraGuide 5-FUTM to audiences of healthcare professionals. It contains slides, supplemental.
Pexelizumab for the Reduction of Infarction and Mortality in Coronary Artery Bypass Graft ll (PRIMO-CABG II) Trial Presented at The American College of.
Putting Statistics to Work
Cholinergic Dysfunction after Traumatic Brain Injury – A PET Study Anna Östberg 1, Jere Virta 2, Juha Rinne 2, Vesa Oikonen 2, Pauliina Luoto 2, Olli Tenovuo*
Revisional Bariatric Surgery Indications and potential benefits.
HIV and Aging Kathleen K Casey, MD Director, AIDS Ambulatory Care Center Jersey Shore University Medical Center.
Transfusion Thresholds in the Elderly Surgical Patient
Leslie Cloud, MD Department of Neurology Division of Movement Disorders Emory University School of Medicine.
© 2005 American Academy of NeurologyFebruary 25, 2004 Practice Parameter: Therapies for Essential Tremor (An Evidence-Based Review) Report of the Quality.
Parkinson's Disease Animal Models and Possible Treatments.
Parkinson’s Disease (PD)
COMPREHENSIVE MANAGEMENT OF PARKINSONIAN PATIENTS WITH BOTULINUM TOXIN MAJA TROŠT DEPARTMENT FOR NEUROLOGY.
Considering the pre-clinical and clinical evidence for continuous dopaminergic stimulation (CDS) This educational material has been supported by Abbott.
Improving The Clinical Care of Children and Adolescents With Mild Traumatic Brain Injury Madeline Joseph, MD, FACEP, FAAP Professor of Emergency Medicine.
Parkinson’s Disease Dr Rachel Cary, Warwick Hospital.
MDS-PAS School for Young Neurologists Video Dinner February 21, 2015 Maria Eliza T. Freitas, MD Clinical Fellow In Movement Disorder University of Toronto.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2014.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Deep Brain Stimulation For parkinson’s disease
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
Amyotrophic Lateral Sclerosis
Duodenal Levodopa Treatment in advanced Parkinson’s Disease
What is the Evidence for Social Care Intervention in the Emergency Department? Introduction  The current health and social care delivery system is not.
Hypothesis of Neural Information Flow about Acupuncture — the new methods of meridian research General Hospital of PLA : Dr. Tong Li Dr. Ling Yin.
LOU GEHRIG’S DISEASE.  Also known as Amyotrophic Lateral Sclerosis  Is a disease of the nerve cells in the brain and spinal cord that control voluntary.
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
AAV2-NRTN (CERE-120) In Parkinson’s Disease: Phase 2 Trial Results and Path Forward Joao Siffert, MD Chief Medical Officer Ceregene, Inc. San Diego, CA.
Motor Response Complications and Cycline-Dependent Kinase 5 (Cdk5) Neuroadaptations in an Animal Model of Parkinson’s Disease Heather Minkel Dr. Justin.
PARKINSON’S DISEASE By Courtney and Niral. WHAT IS IT?  Parkinson's disease (PD) is chronic and progressive movement disorder, meaning that symptoms.
Innovations in Parkinson’s Diagnosis & Treatment: A Personal Story Dr. Kenneth E. Keirstead Excellence in Aging Care Symposium September 25-27, 2013.
Mostly Parkinson’s disease but also few other movement disorders due to diseases of the basal ganglia.
Nervous System Test Review. Nervous System Review Collect Information Analyze Information Initiate Response Central Nervous System Peripheral Nervous.
Note: this Live Meeting is being recorded By participating in this meeting, you agree that your communications may be recorded, including Q & A that may.
Nervous System Diseases & Disorders Notes. Head Trauma #1 cause of trauma deaths in US Many possible mechanisms of injury: Falls Motor vehicle crashes.
PARKINSON’S DISEASE BY: NICOLE MABARDI & SHAINA JOSEPH.
Thien Ngo MD PGY – 3 UK PM&R 5/22/2012 Advisors: Drs. Lumy Sawaki & Oscar Ortiz.
Motor Fatigue in Multiple Sclerosis Jenny Thain - MS Clinical Specialist Physiotherapist, Dr Martin Wilson - Consultant Neurologist Background One of the.
Teaching NeuroImages A 54-year-old man with progressive muscle weakness, hand tremor, tongue and perioral fasciculation Neurology Resident and Fellow Section.
Advisory Committee for Peripheral and Central Nervous System Drugs March 7, 2006 Question 1: 1.Has Biogen demonstrated natalizumab’s efficacy on reduced.
Pathogenesis and pathology of parkinsonism
Efficacy of the Elimination Diet in Children with ADHD: A Systematic Review Lola Achilova Pacific University School of Physician Assistant Studies, Hillsboro,
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Pharmacological Treatment of Parkinson Disease: A.
The Placebo Response and Effect  Can be significant  30% or more in certain interventions  An individual’s overall disease manifestation and treatment.
© 2011 AMERICAN ACADEMY OF NEUROLOGY Update: Treatment of Essential Tremor Report of the Quality Standards Subcommittee of the American Academy of Neurology.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Nervous System Disorders and Homeostatic Imbalances
Ubiquitin Proteasome System in Parkinson's Disease:
WORLD FEDERATION OF NEUROSCIENCE NURSES
Figure 5. Treatment of the checkpoint inhibitor related toxicity
Parkinson's disease KRZYSZTOF NICPOŃ.
Is Spasticity causing Pain
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
Tremor Domina Petric, MD.
Neurodegenerative diseases
Parkinson’s disease. (A) The spiral of the patient with Parkinson’s disease (right) is smaller than the clinician’s, with tighter turns. Parkinson’s disease. (A)
Presentation transcript:

ETIOPATOGENIA EXISTE BASE GENETICA? PORQUE RESPONDE AL OH? QUE ESTRUCTURAS CAUSAN EL TEMBLOR? CUAL ES EL NT MAS IMPORTANTE? EXISTE DETERIORO COGNITIVO? MORTALIDAD ESTA AUMENTADA? CUAL ES LA BASE NEUROPATOLOGICA? INFLUYEN FACTORES DIETETICOS-METABOLICOS? OVERLAP CON OTRAS ENTIDADES EXPERIMENTACION ANIMAL NEUROIMAGEN FUNCIONAL NEUROCIRUGIA FUNCIONAL

¿ EXISTE BASE GENETICA? 50 % AF – AD (65 %) POLIGENICA. PENETRANCIA COMPLETA A LOS 65. DETECCION EN FAMILIAS DE GENES INVOLUCRADOS : Cr. 4 P; 3 Q13 (ETM 1); (D3) 2 P22-25(ETM2) 6p 23 ASOCIACIONES: EP – D – M- CMT

¿QUE ESTRUCTURA CAUSA EL TEMBLOR? PET Hemisferios Cerebelosos Via dento-rubro-talamica- cortical Oscilador talámico Oscilador olivar Aceleración ritmo descarga MNI Oscilador central origina; periferia modula; influencia somatosensitiva. * Hiperfunción via cerebelo talamica (Glutamato), reversible c/OH Estudios de Coherencia (sincronía EMG – NI áreas cer.): varios osciladores según topografía del temblor. NEUROCIRUGIA FUNCIONAL: NVI NEUROPATOLOGÍA: celulas torpedo (Pk), CL, atrofia dentado. ESTIMULACION MAGNETICA TRANSCRANEANA CEREBELO TEMBLOR EN LAS HEREDOATAXIAS DISFUNCIONES OME EN TE

A positron emission tomography study of essential tremor: Evidence for overactivity of cerebellar connections Dr. I. H. Jenkins, MRCP 1 *, P. G. Bain, MRCP 2, J. G. Colebatch, FRACP 1, P. D. Thompson, PhD. 2, L. J. Findley, MD 2, R. S. J. Frackowiak, MD 1, C. D. Marsden, DSc 2, D. J. Brooks, MD 1 1 Medical Research Council (MRC) Cyclotron Unit, Hammersmith Hospital, London, United Kingdom 2 MRC Human Movement and Balance Unit, National Hospital for Neurology and Neurosurgery, London, United Kingdom * Correspondence to I. H. Jenkins, MRC Cyclotron Unit, Hammersmith Hospital, DuCane Road, London W12 OHS, UK ABSTRACT The origin of essential tremor is unknown. Animal models have suggested that the inferior olivary nucleus may act as a tremor generator. We used positron emission tomography to study changes in regional cerebral blood flow associated with involuntary postural tremor and passive wrist oscillation in patients with essential tremor. Activation due to voluntary wrist oscillation and arm extension without tremor was studied in normal control subjects. The essential tremor group had bilaterally increased cerebellar blood flow at rest (without tremor) compared with the control group. Involuntary postural tremor was associated with further bilateral cerebellar activation, and also contralateral striatal, thalamic, and sensorimotor cortex activation. Voluntary wrist oscillation, maintained arm extension without tremor, and passive wrist oscillation were all associated with significant ipsilateral rather than bilateral cerebellar activation. We conclude that essential tremor is associated with increased bilateral cerebellar activity both at rest and during tremor. Received: 24 August 1992; Revised: 27 January 1993; Accepted: 11 February 1993

Lesión o (+) NVI tálamo (eferencia cerebelosa) mejora temblor: normaliza oscilación celular anómala en Hemisferios Cerebelosos

Benito-León J and Louis ED (2006) Essential tremor: emerging views of a common disorder Nat Clin Pract Neurol 2: 666– /ncpneuro0347 Figure 1 Section of cerebellar folium from a patient with essential tremor, showing two torpedoes (arrows) Permission obtained from American Medical Association © Louis ED et al. (2006) Arch Neurol 63: 1189–1193.

Benito- León J and Louis ED (2006) Essential tremor: emerging views of a common disorder Nat Clin Pract Neurol 2: 666– /ncpneuro0347 Figure 2 Section of the dentate nucleus from an individual with essential tremor, showing neuronal loss Permission obtained from American Medical Association © Louis ED et al. (2006) Arch Neurol 63: 1189–1193.

Benito-León J and Louis ED (2006) Essential tremor: emerging views of a common disorder Nat Clin Pract Neurol 2: 666– /ncpneuro0347 Figure 3 Multiple Lewy bodies (arrows) are seen in a section of the locus ceruleus from a patient with essential tremor Permission obtained from AAN Enterprises, Inc. © Louis ED et al. (2006) Neurology 66: 1756–1759.

OH 50 % ¿POR QUÉ? ETANOL MODULA (-) GLUTAMATO A TRAVES DE RECEPTOR NMDA, VIA HIPERACTIVADA EN EL TEMBLOR ESENCIAL.

Eur J Neurol Jul;15(7): Epub 2008 May 15. Links A possible mechanism for the beneficial effect of ethanol in essential tremor. Manto M, Laute MA. Manto MLaute MA Laboratoire de Neurologie Expérimentale, ULB-Erasme, Bruxelles, Belgium. BACKGROUND: Essential tremor is one of the most common movement disorders in elderly people. The hypothesis of a disregulation of N-methyl-D-aspartate (NMDA) pathways has been suggested. It was shown experimentally that infusion of NMDA in cerebellar nuclei down-regulates glutamate release. METHODS: We assessed the effects of intranuclear administration of harmaline on the NMDA-mediated regulation of glutamate in rats using reverse dialysis. We hypothesized that ethanol, which improves essential tremor in the clinic, antagonizes the effect of harmaline upon glutamatergic transmission. We tested the interaction of ethanol and harmaline upon glycerol (a marker of membrane turn-over), lactate, and pyruvate concentrations. RESULTS: Harmaline increased the concentrations of glutamate and impaired the NMDA-mediated regulation of glutamate. Ethanol decreased the concentrations of glutamate during NMDA stimulation in case of pre-administration with harmaline. Concentrations of glycerol rose with harmaline. Glycerol levels markedly decreased during NMDA infusion when inhibitors of nitric oxide synthase, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate antagonists or NMDA antagonists were administered. Harmaline increased lactate/pyruvate ratios during NMDA infusion but these ratios returned to normal values in presence of ethanol. DISCUSSION: We provide a possible mechanism for the beneficial effect of ethanol on essential tremor. The concept of glutamatergic disregulation underlying essential tremor is highlighted. Consequences for our understanding of essential tremor are discussed. PMID: [PubMed - indexed for MEDLINE]

Neurology 2006 ;66;69-74

Ann Neurol Apr;17(4): Association between essential tremor and Parkinson's disease. Geraghty JJ, Jankovic J, Zetusky WJ. To examine a possible relationship of essential tremor to Parkinson's disease (PD), 130 patients with essential tremor were studied. Twenty-five patients had both essential tremor and PD. These 25 patients were matched for age and duration of PD symptoms with 25 patients who had idiopathic PD. Bradykinesia, postural instability, and gait difficulty were more severe in the patients with idiopathic PD. Degree of tremor, rigidity, and functional disability did not differ in the two groups. The prevalence of PD in the population with essential tremor was 24 times greater than expected. This study suggests that some patients with essential tremor have a genetically increased risk for PD. PMID: [PubMed - indexed for MEDLINE] Geraghty JJJankovic JZetusky WJ

Muscle Nerve Sep;16(9): Links Hereditary motor-sensory neuropathy and movement disorders. Cardoso FECardoso FE, Jankovic J.Jankovic J Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas To explore the relationship between hereditary motor and sensory neuropathy (HMSN) and movement disorders, we examined 7 patients with HMSN referred to our Movement Disorders Clinic and surveyed members of the Charcot-Marie-Tooth association. The following movement disorders were observed in the index patients: postural tremor in 6, rest tremor in 3, and Parkinsonism and dystonia in 2. Tremor, present in 40% of the 201 patients who responded to the survey, was first noted at a mean age of 36 years, and mostly involved the hands. Family history of tremor was more frequent in the tremor group (P < 0.005), which also had a significantly worse writing score than the nontremor group (P < 0.001). The overlap in clinical features between HMSN-associated tremor and essential tremor (ET), the high frequency of family history of tremor, and the lack of a relationship between the severity of tremor and of peripheral neuropathy suggest that the tremor in HMSN is pathogenically related to ET. PMID: [PubMed - indexed for MEDLINE]

E. D. Louis, W. Zheng, X. Mao, and D. C. Shungu Blood harmane is correlated with cerebellar metabolism in essential tremor: A pilot study Neurology, August 7, 2007; 69(6): Mov Disord Mar;20(3): Links Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications. Martin FCMartin FC, Thu Le A, Handforth A.Thu Le AHandforth A Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California 90073, USA. No preclinical method to evaluate potential new medications for essential tremor (ET) is available currently. NEUROLOGY 2005;65: © 2005 American Academy of NeurologyAmerican Academy of Neurology Blood harmane concentrations and dietary protein consumption in essential tremor E. D. Louis, MD, MS, W. Zheng, PhD, L. Applegate, BA, L. Shi, MS and P. Factor-Litvak, PhD Conclusions: The similarity between patients and controls in daily animal protein consumption and the absence of the normal correlation between daily animal protein consumption and logHA in patients suggests that another factor (e.g., a metabolic defect) may be increasing blood harmane concentration in patients.

Benito- León J and Louis ED (2006) Essential tremor: emerging views of a common disorder Nat Clin Pract Neurol 2: 666– /ncpneuro0347 Figure 4 Archimedean spirals drawn by individuals with and without essential tremor TRATAMIENTO

IDENTIFICAR CAUSAS: INTERROGAR - TSH EXPLICAR Q NO PADECE EP NO TRATAR SI NO INTERF. FUNCIONALIDAD IDENTIFICAR y FAVORECER CONDUCTAS (-) EL TRATAMIENTO ES SINTOMATICO LARGO PLAZO A MENUDO MAL TOLERADO CONTRAINDICACIONES

CAUSAS DE TEMBLOR EMOCIONES: ANSIEDAD STRESS MIEDO FATIGA HIPOGLICEMIA HIPERTIROIDISMO FEOCROMOCITOMA FARMACOS

ALCOHOL NIVEL de EVIDENCIA II-B 1 – 2 TRAGOS ALCOHOL ETILICO REDUCE 75 % el TEMBLOR EN % de los PACIENTES TRANSITORIO: 45 – 60 MINUTOS PUEDE DESARROLLARSE TOLERANCIA ADVERTIR EVITAR ABUSO EL RIESGO DE ADICCION ES BAJO

ALPRAZOLAM 0,25 – 1 mgs. v/o HORAS ANTES DE UN EVENTO

Neurology 2005;64; ; originally published online Jun 22, 2005 ; This information is current as of August 20, 2008

Abstract—Background: Essential tremor (ET) is one of the most common tremor disorders in adults and is characterized by kinetic and postural tremor. To develop this practice parameter, the authors reviewed available evidence regarding initiation of pharmacologic and surgical therapies, duration of their effect, their relative benefits and risks, and the strength of evidence supporting their use. Methods: A literature review using MEDLINE, EMBASE, Science Citation Index, and CINAHL was performed to identify clinical trials in patients with ET published between 1966 and August Articles were classified according to a four-tiered level of evidence scheme and recommendations were based on the level of evidence. Results and Conclusions: Propranolol and primidone reduce limb tremor (Level A). Alprazolam, atenolol,gabapentin (monotherapy), sotalol, and topiramate are probably effective in reducing limb tremor (Level B). Limitedstudies suggest that propranolol reduces head tremor (Level B). Clonazepam, clozapine, nadolol, and nimodipine possibly reduce limb tremor (Level C). Botulinum toxin A may reduce hand tremor but is associated with dose-dependent hand weakness (Level C). Botulinum toxin A may reduce head tremor (Level C) and voice tremor (Level C), but breathiness, hoarseness, and swallowing difficulties may occur in the treatment of voice tremor. Chronic deep brain stimulation (DBS) (Level C) and thalamotomy (Level C) are highly efficacious in reducing tremor. Each procedure carries a small risk of major complications. Some adverse events from DBS may resolve with time or with adjustment of stimulator settings. There is insufficient evidence regarding the surgical treatment of head and voice tremor and the use of gamma knife thalamotomy (Level U). Additional prospective, double-blind, placebo-controlled trials are needed to better determine the efficacy and side effects of pharmacologic and surgical treatments of ET. NEUROLOGY 2005;64:2008–2020

B-BLOQUEANTES PROPANOLOL (OTROS: TIMOLOL NADOLOL SOTALOL METOPROLOL) NIVEL DE EVIDENCIA I-A (DE ELECCION) (-) REC. B2 PERIFERICOS, TB. PROBABLE CENTRAL B1 CONTRAINDICACIONES: INS. CARD (II-III); DM, ASMA, EPOC, AOC, BAV 2-3. EFECTOS SECUNDARIOS: FATIGA, IMPOTENCIA, DEPRESION, HIPOTENSION, ARRITMIAS.

PROPANOLOL DOSIS INDIVIDUALIZADA EFECTO NO ES DOSIS DEPENDIENTE 40 mg 1 VEZ AL DIA POR 3 DIAS AUMENTAR 40 mg CADA 3 DIAS HASTA 120 (EN 3 TOMAS O PREPARADOS DE ACCION PROLONGADA) SI NO HAY RESPUESTA AUMENTAR A 160 mg/dia. SI NO RESPONDE RETIRAR GRADUALMENTE (AUNQUE HASTA 320 PUEDE HABER RESPUESTA) CONTROLA EL TEMBLOR EN UN 50%, S/T MANOS, EN 50 – 70% DE LOS PACIENTES, ALGUNOS RESPUESTA NOTABLE, OTROS NO RESPONDEN

PRIMIDONA REDUCE % TEMBLOR EN 50 – 70 % DE LOS PACIENTES, S/T MANOS. EVIDENCIA I-A BARBITURICO METABOLIZA A FENOBARBITAL, PERO SU ACCION ANTITEMBLOR ES INDEPENDIENTE, PROBABLEMENTE CENTRAL INICIAR EN DOSIS BAJAS 62,5 mg. (1/4 comp. 250) *NO HAY COMP DE 50 o 60*. DE NOCHE. CADA 3 DIAS PASAR A ½ COMP., LUEGO ¾, LUEGO 1. SI NO BASTA DOSIS UNICA NOCTURNA DE 250 mg, AGREGAR 1 o 2 tomas mas de ½ COMP (125) EN LA M y la T. FRECUENTE INTOLERANCIA 25 % (VARIABLE, FARMACOGENETICA): HIPERSOMNIA, MAREOS, VERTIGOS, NAUSEAS, OBNUBILACION, COMA, RASH. 24 – 72 % SE ALIVIA.

Zesiewicz, T. A. et al. Neurology 2005;64:

Benito- León J and Louis ED (2006) Essential tremor: emerging views of a common disorder Nat Clin Pract Neurol 2: 666– /ncpneuro0347 Table 1 Pharmacological agents for the treatment of essential tremor

Zesiewicz, T. A. et al. Neurology 2005;64: